Clinical trial · Interventional
Vitamin D/Calcium Polyp Prevention Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Extensive experimental and observational data suggest that intake of calcium and of vitamin D exert protective effects on colorectal neoplasia. Building on their previous work, the investigators will investigate the chemopreventive effect of vitamin D in the large bowel, to study whether calcium with vitamin D is more effective than calcium alone, and to confirm their positive finding regarding calcium. The goal of this study is the development of chemopreventive combinations that will reduce risk of colorectal neoplasia sufficiently to permit the lengthening of surveillance intervals in most patients and to clarify important issues regarding the mechanisms of colorectal carcinogenesis and chemoprevention.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adenomas | Adenoma | ALIAS | 0.90 |
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Polyps | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Calcium Carbonate | Drug | — | UNRESOLVED |
| placebo | Drug | — | UNRESOLVED |
| Vitamin D3 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (6)
- type
- EXPERIMENTAL
- label
- Full Factorial Placebo
- description
- subjects in 2X2 factorial design; randomized to daily placebo
- interventionNames
- Drug: placebo
- type
- EXPERIMENTAL
- label
- Full Factorial Calcium
- description
- subjects in 2X2 factorial design; randomized to daily 1200 mg as calcium carbonate
- interventionNames
- Drug: Calcium Carbonate
- type
- EXPERIMENTAL
- label
- Full Factorial Vitamin D
- description
- Subjects in 2X2 factorial design; randomized to daily 1000 IU vitamin D3
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 45 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * One or more histologically verified neoplastic polyp (adenoma) that is at least 2 mm in size removed from the large bowel with the entire large bowel examined by colonoscopy and documented to be free of further polyps or areas suspicious for neoplasia within 120 days of study entry * Anticipated colonoscopic follow-up three years or five years after the qualifying colonoscopy * Age between 45 and 75 years at enrollment * (Women)Agreement to avoid pregnancy (i.e., use of standard contraception) * Willingness to forego calcium supplementation (including multivitamins containing calcium) or, for women only, option of taking calcium supplementation of 1200 mg/daily (contained in the study pills) * Willingness to forego vitamin D supplementation (including multivitamins containing vitamin D) * Agreement to daily dietary intake of the equivalent of not more than 1200 mg calcium * Agreement to daily dietary intake of the equivalent of not more than 400 IU vitamin D * Blood calcium level within normal range * Blood creatinine level not to exceed 20% above upper limit of normal * Serum 25-(OH)-vitamin D within lower limit of normal to 70 ng/ml * Ability and willingness to follow the study protocol, as indicated by provision of informed consent to participate * Good general health, with no severely debilitating diseases or active malignancy that might compromise the patient's ability to complete the study Exclusion Criteria: General exclusionary criteria: * Participation in another colorectal (bowel) study (intervention study) in the past 5 years * Current participation in any other clinical trial (intervention study) * Pregnancy or lactation * A diagnosis of narcotic or alcohol dependence in the past 5 years * A diagnosis of dementia (e.g. Alzheimer's) in the past 5 years * A diagnosis of a significant psychiatric disability (e.g. Schizophrenia, refractory bipolar disorder, current severe depression) in the past 5 years Exclusions due to derangement of calcium metabolism or indications /contraindications to study agents: * Any diagnosis of kidney stones * A diagnosis of granulomatous diseases, e.g. sarcoidosis, active chronic fungal or mycobacterial infections (tuberculosis, histoplasmosis, coccidioidomycosis, blastomycosis), berylliosis, Wegener's granulomatosis in the past 5 years * A diagnosis of hyperparathyroidism or other serious disturbance of calcium metabolism in the past 5 years * A diagnosis of severe kidney disease, e.g. chronic renal failure in the past 5 years * A diagnosis of unexplained hypercalcemia in the past 5 years * Any Diagnosis of osteoporosis with physician recommendation for treatment of low bone mass * A diagnosis of two or more low trauma fractures in the past 5 years * A diagnosis of a medical condition requiring treatment with vitamin D (e.g. osteomalacia) in the past 5 years Exclusions due to intestinal or bowel problems: * Any diagnosis of invasive carcinoma of the large bowel (even if confined to a polyp) * Any diagnosis of familial colorectal cancer syndromes, e.g. Familial Adenomatous Polyposis (FAP) (including Gardner syndrome, Turcot's syndrome), Hereditary Nonpolyposis Colorectal Cancer (HNPCC), Hamartomatous Polyposis syndromes (including Peutz-Jeghers or Familial Juvenile Polyposis) * Any diagnosis of inflammatory bowel disease, e.g. Crohn's Disease, Ulcerative Colitis * A diagnosis of chronic intestinal malabsorption syndromes, e.g. celiac sprue, bacterial overgrowth, chronic pancreatitis, pancreatic insufficiency in the past 5 years * Any large bowel resection Exclusions due to poor health: * A diagnosis of malignancy, other than non-melanoma skin cancer in the past 5 years * A diagnosis of severe lung disease - class 3 or 4 (e.g. chronic obstructive pulmonary disease or emphysema requiring oxygen) in the past 5 years * A diagnosis of severe heart disease: cardiovascular disease functional class 3 or 4 in the past 5 years * Any diagnosis of severe liver disease, e.g. cirrhosis Exclusions due to shipping regulations: * Any current/past HIV positive diagnosis * Active hepatitis B, defined as : Hep B surface antigen positive * Active hepatitis C, defined as : measurable hepatitis C RNA Drug exclusions: * Use of chronic oral corticosteroid therapy in the past 5 years * Use of lithium in the past 5 years * Use of phenytoin's in the past 5 years * Use of quinidine in the past 5 years * Use of therapeutic vitamin D in the past 5 years
References
Publications (13)
- DERIVEDGibbs DC, Barry EL, Fedirko V, Baron JA, Bostick RM. Impact of Common Vitamin D-Binding Protein Isoforms on Supplemental Vitamin D3 and/or Calcium Effects on Colorectal Adenoma Recurrence Risk: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2023 Apr 1;9(4):546-551. doi: 10.1001/jamaoncol.2022.6924. PMID 36701139
- DERIVEDPassarelli MN, Mott LA, Barry EL, Rees JR, Baron JA. Oral Antibiotics and Risk of New Colorectal Adenomas During Surveillance Follow-up. Cancer Epidemiol Biomarkers Prev. 2021 Oct;30(10):1974-1976. doi: 10.1158/1055-9965.EPI-21-0323. Epub 2021 Jul 21. PMID 34289971
- DERIVEDPassarelli MN, Karagas MR, Mott LA, Rees JR, Barry EL, Baron JA. Risk of keratinocyte carcinomas with vitamin D and calcium supplementation: a secondary analysis of a randomized clinical trial. Am J Clin Nutr. 2020 Dec 10;112(6):1532-1539. doi: 10.1093/ajcn/nqaa267. PMID 33022713
- DERIVEDCrockett SD, Barry EL, Mott LA, Ahnen DJ, Robertson DJ, Anderson JC, Wallace K, Burke CA, Bresalier RS, Figueiredo JC, Snover DC, Baron JA. Calcium and vitamin D supplementation and increased risk of serrated polyps: results from a randomised clinical trial. Gut. 2019 Mar;68(3):475-486. doi: 10.1136/gutjnl-2017-315242. Epub 2018 Mar 1. PMID 29496722
- DERIVEDAnderson JC, Morris CB, Robertson DJ, Barry ELR, Figueiredo JC, Cruz-Correa M, Bostick RM, Ahnen DJ, Baron JA. Can the Sum of Adenoma Diameters (Adenoma Bulk) on Index Examination Predict Risk of Metachronous Advanced Neoplasia? J Clin Gastroenterol. 2018 Aug;52(7):628-634. doi: 10.1097/MCG.0000000000000899. PMID 28767463
- DERIVEDBarry EL, Peacock JL, Rees JR, Bostick RM, Robertson DJ, Bresalier RS, Baron JA. Vitamin D Receptor Genotype, Vitamin D3 Supplementation, and Risk of Colorectal Adenomas: A Randomized Clinical Trial. JAMA Oncol. 2017 May 1;3(5):628-635. doi: 10.1001/jamaoncol.2016.5917. PMID 27978548